| Literature DB >> 30755422 |
Helen M McRae1,2, Alexandra L Garnham1,2, Yifang Hu1, Matthew T Witkowski1,2, Mark A Corbett3, Mathew P Dixon1, Rose E May1, Bilal N Sheikh1,2, William Chiang1,2, Andrew J Kueh1,2, Tan A Nguyen1,2, Kevin Man1,2, Renee Gloury1, Brandon J Aubrey1,2, Antonia Policheni1,2, Ladina Di Rago1, Warren S Alexander1,2, Daniel H D Gray1,2, Andreas Strasser1,2, Edwin D Hawkins1,2, Stephen Wilcox1,2, Jozef Gécz3, Axel Kallies1,2, Matthew P McCormack4, Gordon K Smyth1,5, Anne K Voss1,2, Tim Thomas1,2.
Abstract
Somatically acquired mutations in PHF6 (plant homeodomain finger 6) frequently occur in hematopoietic malignancies and often coincide with ectopic expression of TLX3. However, there is no functional evidence to demonstrate whether these mutations contribute to tumorigenesis. Similarly, the role of PHF6 in hematopoiesis is unknown. We report here that Phf6 deletion in mice resulted in a reduced number of hematopoietic stem cells (HSCs), an increased number of hematopoietic progenitor cells, and an increased proportion of cycling stem and progenitor cells. Loss of PHF6 caused increased and sustained hematopoietic reconstitution in serial transplantation experiments. Interferon-stimulated gene expression was upregulated in the absence of PHF6 in hematopoietic stem and progenitor cells. The numbers of hematopoietic progenitor cells and cycling hematopoietic stem and progenitor cells were restored to normal by combined loss of PHF6 and the interferon α and β receptor subunit 1. Ectopic expression of TLX3 alone caused partially penetrant leukemia. TLX3 expression and loss of PHF6 combined caused fully penetrant early-onset leukemia. Our data suggest that PHF6 is a hematopoietic tumor suppressor and is important for fine-tuning hematopoietic stem and progenitor cell homeostasis.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30755422 PMCID: PMC6695515 DOI: 10.1182/blood-2018-07-860726
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113